...
首页> 外文期刊>Biomaterials >Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
【24h】

Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types

机译:用肿瘤坏死因子相关的凋亡诱导配体和转铁蛋白表面修饰的载有阿霉素的人血清白蛋白纳米颗粒,可靶向多种肿瘤

获取原文
获取原文并翻译 | 示例

摘要

Human serum albumin (HSA) nanoparticles (NPs) surface modified with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and transferrin, and containing doxorubicin were designed and prepared. Surface amines of HSA were reversibly protected with dimethylmaleic anhydride (DMMA), and HSA-NPs were prepared using a desolvation technique. Furthermore, the surfaces of HSA-NPs were modified with thiolated TRAIL or transferrin using sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC). The prepared TRAIL/transferrin plus doxorubicin HSA-NPs were characterized by TEM, FE-SEM, and particle size analysis, and their cytotoxic and apoptotic activities were evaluated in several cancer cell lines, namely, HCT 116, doxorubicin-resistant MCF-7, and CAPAN-1. In addition, the tumor-targeting abilities of NPs were assessed using an infrared imaging system in HCT 116-xenografted nu/. nu mice. Results showed that the TRAIL/transferrin/doxorubicin HSA-NPs had remarkable cytotoxic and apoptotic activities in all cancer cells examined with a general or a drug-resistant character, and that these NPs had obvious synergistic cytotoxic effects particularly on CAPAN-1 cells. Moreover, these HSA-NPs were effectively localized to tumors in a HCT 116-xenografted nu/. nu mouse over 32 h. The findings of this study suggest that the described TRAIL/transferrin/doxorubicin HSA-NPs are a useful targeting agent capable of killing different types of tumor cells in various tissue organs.
机译:设计并制备了经肿瘤坏死因子(TNF)相关的凋亡诱导配体(TRAIL)和转铁蛋白表面修饰的人血清白蛋白(HSA)纳米颗粒(NPs),并含有阿霉素。 HSA的表面胺被二甲基马来酸酐(DMMA)可逆地保护,并且HSA-NP使用去溶剂化技术制备。此外,使用硫代琥珀酰亚胺基-4-(N-马来酰亚胺基甲基)环己烷-1-羧酸酯(Sulfo-SMCC),用硫醇化的TRAIL或转铁蛋白修饰HSA-NP的表面。通过TEM,FE-SEM和粒度分析对制得的TRAIL /转铁蛋白加阿霉素HSA-NPs进行表征,并在几种癌细胞系HCT 116,对阿霉素耐药的MCF-7,和CAPAN-1。此外,在HCT 116异种移植nu /中使用红外成像系统评估了NPs的肿瘤靶向能力。 nu小鼠。结果表明,TRAIL /转铁蛋白/阿霉素HSA-NP在所有具有一般或耐药性的癌细胞中均具有显着的细胞毒性和凋亡活性,并且这些NP具有明显的协同细胞毒性作用,尤其是对CAPAN-1细胞。而且,这些HSA-NPs有效地定位于HCT 116异种移植的nu /中的肿瘤。 nu鼠标超过32小时。这项研究的发现表明,所描述的TRAIL /转铁蛋白/阿霉素HSA-NP是一种有用的靶向剂,能够杀死各种组织器官中不同类型的肿瘤细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号